Shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) saw strong trading volume on Thursday . 85,722 shares were traded during trading, an increase of 13% from the previous session’s volume of 75,592 shares.The stock last traded at $21.02 and had previously closed at $20.75.

A number of research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Aclaris Therapeutics from a “hold” rating to a “sell” rating in a research report on Tuesday, May 24th. Guggenheim initiated coverage on shares of Aclaris Therapeutics in a research note on Friday, June 10th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Jefferies Group restated a “buy” rating and set a $20.00 price target on shares of Aclaris Therapeutics in a research note on Sunday, March 27th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $28.50.

The company’s market cap is $426.23 million. The firm’s 50 day moving average is $19.73 and its 200-day moving average is $19.51.

Aclaris Therapeutics (NASDAQ:ACRS) last announced its earnings results on Wednesday, May 11th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.50) by $0.15. On average, equities analysts expect that Aclaris Therapeutics Inc. will post ($2.45) earnings per share for the current year.

An institutional investor recently bought a new position in Aclaris Therapeutics stock. Turner Investments L.P. bought a new stake in shares of Aclaris Therapeutics Inc. (NASDAQ:ACRS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 57,694 shares of the company’s stock, valued at approximately $1,554,000. Turner Investments L.P. owned 0.29% of Aclaris Therapeutics as of its most recent filing with the SEC.

Aclaris Therapeutics, Inc is a United States-based clinical-stage specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing differentiated therapies in dermatology. The Company’s drug candidate, A-101 is being developed as an in-office treatment for seborrheic keratosis, a non-cancerous skin tumor, as well as for other cutaneous indications, such as common warts.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.